Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 461 to 470 of 1003 total matches.

Emergency Contraception OTC

   
The Medical Letter on Drugs and Therapeutics • Feb 02, 2004  (Issue 1175)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D ...
An FDA Advisory Committee has recommended over-the-counter (OTC) marketing of Plan B (Barr), an emergency contraceptive "pill pack" that contains two 0.75-mg tablets of levonorgestrel to be taken 12 hours apart (Medical Letter 2000; 42:10). Plan B is one of two FDA-approved products for this indication. The Preven Emergency Contraceptive Kit (Medical Letter, 40:102, 1998) includes four tablets, each containing 0.25 mg of levonorgestrel and 50 ╡g of ethinyl estradiol; these are taken 2 at a time 12 hours apart (the "Yuzpe regimen") and are available only by...
Med Lett Drugs Ther. 2004 Feb 2;46(1175):10-1 |  Show IntroductionHide Introduction

An Injectable Hyaluronic Acid (Restylane) for Wrinkles

   
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004  (Issue 1177)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
An injectable gel of hyaluronic acid (Restylane) has been approved by the FDA for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Manufactured by Q-Med AB, a Swedish company, it has been used outside the US since 1996.
Med Lett Drugs Ther. 2004 Mar 1;46(1177):17-8 |  Show IntroductionHide Introduction

Pemetrexed (Alimta) for Mesothelioma

   
The Medical Letter on Drugs and Therapeutics • Apr 12, 2004  (Issue 1180)
. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba; Neal H ...
The combination of pemetrexed (Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been linked to asbestos exposure, was previously considered unresponsive to chemotherapy, with a median survival of 6-8 months from diagnosis (VW Rusch, J Clin Oncol 2003; 21:2629).
Med Lett Drugs Ther. 2004 Apr 12;46(1180):31-2 |  Show IntroductionHide Introduction

Viagra and Loss of Vision

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2005  (Issue 1211)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
The FDA recently announced that it was investigating 38 reports of loss of vision in men who took sildenafil (Viagra), which has been used to treat erectile dysfunction since 1998.
Med Lett Drugs Ther. 2005 Jun 20;47(1211):49 |  Show IntroductionHide Introduction

Lenalidomide (Revlimid) for Anemia of Myelodysplastic Syndrome

   
The Medical Letter on Drugs and Therapeutics • Apr 10, 2006  (Issue 1232)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Lenalidomide (Revlimid - Celgene), a thalidomide analog, has been approved by the FDA for treatment of patients with transfusion-dependent anemia due to myelodysplastic syndrome (MDS) associated with a 5q deletion cytogenetic abnormality and a low or low-intermediate risk of mortality and progression to leukemia (based on the International Prognostic Scoring System).
Med Lett Drugs Ther. 2006 Apr 10;48(1232):31-2 |  Show IntroductionHide Introduction

Aspirin for Primary Prevention of Cardiovascular Disease (Revisited)

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006  (Issue 1238)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
When the use of aspirin for primary prevention of cardiovascular diseases was last reviewed in The Medical Letter, only one placebo-controlled prospective trial was available: the (male) Physicians' Health Study. Last year, a second large, randomized, placebo-controlled study was reported as part of the Women's Health Study. Recently a sex-specific meta-analysis of 6 trials, including these two, was published.
Med Lett Drugs Ther. 2006 Jul 3;48(1238):53 |  Show IntroductionHide Introduction

A Second Dose of Varicella Vaccine

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006  (Issue 1244)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
...
Med Lett Drugs Ther. 2006 Sep 25;48(1244):79-80 |  Show IntroductionHide Introduction

Tadalafil (Cialis) Once a Day for Erectile Dysfunction

   
The Medical Letter on Drugs and Therapeutics • Apr 07, 2008  (Issue 1283)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil (Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil (Viagra) and vardenafil (Levitra), the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.
Med Lett Drugs Ther. 2008 Apr 7;50(1283):27-8 |  Show IntroductionHide Introduction

Ezetimibe Revisited

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008  (Issue 1293)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
In recent months, both the lay media and some medical experts have raised concerns about the effectiveness and safety of ezetimibe, a widely used drug that prevents absorption of cholesterol from the GI tract. Ezetimibe is available alone as Zetia and in combination with 10, 20, 40 and 80 mg of simvastatin (Zocor, and others) as Vytorin.
Med Lett Drugs Ther. 2008 Aug 25;50(1293):67-8 |  Show IntroductionHide Introduction

In Brief: Cardiac Risks of Antipsychotic Drugs

   
The Medical Letter on Drugs and Therapeutics • Feb 23, 2009  (Issue 1306)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
A recently published retrospective cohort study in patients 30-74 years old has led to headlines in the media warning that use of atypical antipsychotic drugs doubles patients’ risk of sudden cardiac death. Typical antipsychotics have long been associated with this risk. In this study, however, the incidence of sudden cardiac death was similar with typical and atypical antipsychotics: about 1 in 340 person-years among the patients who took typical (first generation) antipsychotics such as haloperidol (Haldol, and others) and 1 in 360 personyears among those who took atypical...
Med Lett Drugs Ther. 2009 Feb 23;51(1306):13 |  Show IntroductionHide Introduction